Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

NCT: NCT06453460 · RECRUITING

NCT IDNCT06453460
StatusRECRUITING
Start Date2024-06-27
Completion2029-06
SponsorUniversity of California, Irvine (OTHER)
First posted
Last updated

Brief Summary

This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

Frequently Asked Questions

What is CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT?

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT is a clinical trial registered under NCT06453460. Current status: RECRUITING.

What is the status of NCT06453460?

The current status of NCT06453460 (CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT) is: RECRUITING.

When did CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT start?

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT started on 2024-06-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑